- Chickenpox vaccine does not appear to increase incidence of shingles, study finds
- Study: Pharmacist intervention improves shingles vaccine rate
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Study: Whooping cough vaccine may not prevent infection
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
BARRINGTON, Ill. —Merix Pharmaceutical unveiled its new Fast-Results! genital herpes treatment March 1. The only over-the-counter treatment for genital herpes, Fast-Results! answers an unmet need of people who suffer painful symptoms associated with genital herpes outbreaks, and it can be used in conjunction with a prescription therapy for genital herpes.
Fast-Results! genital herpes treatment is comprised of Merix’s patented technology Viracea, which contains an approved ingredient under the Food and Drug Administration OTC antiseptic/antimicrobial monograph, the company stated.
According to the Centers for Disease Control and Prevention, 16% of Americans currently suffer from genital herpes.
No matter how the herpes treatment is categorized, it should drive traffic. According to Nielsen Group data for the 52 weeks ended Feb. 20 across food, drug and mass, all lip remedies were relatively flat, up only 0.7% to $530.7 million. Foot preparations, which include jock itch remedies and other antifungals, totaled $193.6 million in sales, down 7.4%.